Implantable tiny telescope works in four patients; Israel pushes life sciences incubator fund;

 @FierceMedDev: St. Jude stands firm despite more Durata scrutiny. More | Follow @FierceMedDev

 @DamianFierce: In case you missed it, Intuitive Surgical shareholders are suing, claiming $ISRG withheld da Vinci problems. Article | Follow @DamianFierce

 @MarkHFierce: Slow going for J&J's absorption of  its massive Synthes acquisition,  via Finance und Wirtschaft (translation req.). Story | Follow @MarkHFierce

 @MichaelGFierce: Med tech lender MidCap readies for potential buyout. More | Follow @MichaelGFierce

> Cardiovascular Systems ($CSII) says data from its CONFIRM study series shows the company's orbital atherectomy system to treat peripheral artery disease had few problems in patients with and without renal disease. Item

> An implantable miniature telescope developed by VisionCare Ophthalmic Technologies to treat macular degeneration has shown promise as a corrective device in its first four patients. Story

> Gynecological diagnostic and surgical procedures will increasingly be performed in doctor's offices and at ambulatory surgical centers as the market becomes increasingly competitive, Millennium Research Group concludes in a new report. Item

> Cornell University engineers say that a smartphone-based system could help diagnose AIDS-related Kaposi's sarcoma through the use of gold nanoparticles combined with DNA snippets. Item

> Israel is launching an incubator fund intended, in part, to help draw further multinational investment in the country's already growing medical devices industry. Story

> In vitro diagnostics are growing at double the rate of the global pharmaceutical industry in some segments, Frost & Sullivan concludes in a new report. Item

Biotech News

 @FierceBiotech: From FierceBiotechIT.com: Pharma giant Boehringer Ingelheim backs startup program Rock Health. Article | Follow @FierceBiotech

 @JohnCFierce: Celgene's Revlimid OK'd for mantle cell lymphoma. Release | Follow @JohnCFierce

 @RyanMFierce: Endo announces about 700 job cuts fresh from FDA denial of testosterone drug, facing generics competition. Release | Follow @RyanMFierce

 @EmilyMFierce: One in 6 NIH research grant proposals get funding. That will be exacerbated by sequestration. Story | Follow @EmilyMFierce

> Biotech vet Westphal to exit CEO post of cancer drug developer Verastem. News

> Endo to slash 700 jobs after FDA setbacks. Article

> Pfizer turns to upstart CytomX for $635M deal on armed antibody tech. News

Pharma News

 @FiercePharma: Sky-high drug prices will force change in cancer care, experts say, may save costs elsewhere. Yesterday's story | Follow @FiercePharma

 @EricPFierce: Neptune starts work on its new omega 3 plant in Canada where last year's fatal explosion leveled operations. Article | Follow @EricPFierce

 @CarlyHFierce: Avandia Adcomm hearings recap, Day 1: Article | Follow @CarlyHFierce

> Endo to cut 700 jobs, review asset sales in major restructuring. Article

> FDA official, panelists challenge Avandia safety trial. More

Pharma Manufacturing News

> Boehringer China biologics plant to do contract work. Story

> Impax cuts 110 jobs tied to problems at plant. Report

> Sanofi ramps up insulin production at Russian plant. News

> FDA issues warning letter for Novartis Ebewe plant. Article

Vaccines News

> FDA lifts clinical hold on anthrax vaccine. Item

> HPV vax awareness uneven despite Merck ad blitz. Report

> Novavax makes $30M bid for adjuvant business. Story

> U.S. pathogen team to locate in China CDC. More

> More New Yorkers skipping vaccines on religious grounds. Article

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.